Search Bar & Filters
Found 26 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.
Actively Recruiting
Researchers are conducting an observational study called AMIPE to collect and analyze data on patients with acute coronary syndrome or myocardial injury. The study is both retrospective and prospective, enrolling patients admitted to participating hospitals from January 1, 2016, to December 31, 2023. The goal is to improve understanding and knowledge about these heart conditions by creating a detailed database of patient characteristics and outcomes. The study involves gathering information from patient medical records during hospitalization and requires written informed consent for prospective participants. No specific treatments are assigned as this is an observational study all diagnostic and therapeutic interventions follow established guidelines and good clinical practice. Researchers will document patient characteristics, long-term outcomes, and treatment regimens. Participants will be monitored for major outcomes such as all-cause mortality and major adverse cardiac events over 1, 3, and 5 years. Additional data on cardiovascular risk factors, clinical presentations, and complications will also be collected. Statistical analyses including univariate and multivariate methods will be used to evaluate these outcomes. The study is led by IRCCS Azienda Ospedaliero-Universitaria di Bologna and aims to provide new scientific evidence about these heart conditions.
Actively Recruiting
Researchers are evaluating the clinical characteristics and procedural outcomes of patients receiving permanent cardiac pacing to treat various heart rhythm disorders. This observational study compares the effectiveness and safety of different device implantation methods used in routine clinical practice, including the contribution of advanced non-fluoroscopic anatomical and electrophysiological mapping systems. The study focuses on patients over 18 years old who require a pacemaker or intracardiac defibrillator implant following European Society of Cardiology guidelines. The study includes several types of cardiac pacing approaches conventional right ventricular pacing, conduction system pacing such as His bundle or left bundle branch area pacing, cardiac resynchronization therapy CRT with biventricular or left ventricular pacing, epicardial pacing often done during cardiac surgery, and leadless pacing via a percutaneous femoral vein approach. Each method involves implantation of a device connected to cardiac leads positioned in specific heart locations, with vascular access through veins like the cephalic, axillary, or subclavian. Electrical parameters such as pacing threshold and sensing are measured to ensure device stability before final placement. Participants will be followed for up to 120 months with clinical and procedural data collected, including assessments of device efficacy and safety at 30 days, 6 months, and 12 months. Outcome measures include stable electrical device performance, absence of cardiovascular hospitalizations or death, and monitoring for heart failure or arrhythmia events. The study also tracks procedural times, radiation exposure, and complications such as infections or lead dislocations. This long-term observation aims to understand the benefits and risks of various pacing strategies in real-world settings.
Actively Recruiting
Researchers are evaluating the current main criteria used to diagnose placenta accreta and studying the maternal outcomes related to different management strategies for suspected placental accretism. The goal is to better understand the complications and improve standardization of care for affected pregnant women aged 18 to 44 years. This observational study is both retrospective and prospective and conducted across multiple centers nationally. Patients will receive treatment based on usual clinical practice. The study will collect and analyze key imaging and instrumental findings from cases of suspected accretism. It will compare outcomes between conservative management cesarean section with placenta left in place and more radical management cesarean section with concurrent hysterectomy. Monitoring includes vital signs, laboratory tests, ultrasound, and other examinations during pregnancy, immediate postpartum, and follow-up visits. Participants will have visits twice a week during pregnancy unless complications arise. Postpartum follow-up depends on the procedure performed and any complications. Researchers will assess the agreement between prenatal diagnosis and surgical findings, as well as maternal complications such as surgical site infection up to one month after delivery. No questionnaires or rating scales are used. The study runs until December 31, 2026.
Actively Recruiting
This research aims to study the epidemiology of invasive bacterial diseases caused by Streptococcus pneumoniae pneumococcus, Neisseria meningitidis meningococcus, and Haemophilus influenzae hemophilus. These infections can cause severe illness and serious complications. The study focuses on monitoring these infections to guide public health efforts, evaluate vaccine impacts, and plan prevention and treatment strategies by identifying circulating strains and assessing vaccine failures. The study uses molecular diagnostic testing to identify these bacteria from blood samples, even when traditional culture methods may fail due to prior antibiotic use or sample handling issues. Pediatric and adult patients diagnosed with invasive bacterial diseases caused by these pathogens are included. This approach enables more accurate detection and characterization of the bacteria. Participants diagnosed with these invasive bacterial infections will have their samples analyzed using molecular methods. Researchers will monitor the incidence rates of these infections in children, the distribution of bacterial types, and the proportion of cases preventable by vaccination. The study will also assess vaccine failure rates. The average study duration for outcome measurement is about one year, supporting improved surveillance and public health interventions.
Actively Recruiting
Researchers are studying recurrent bacterial vaginosis, a common condition in women of reproductive age caused by an imbalance in vaginal bacteria. This trial evaluates whether a probiotic supplement containing Lactobacillus crispatus CRP21 can reduce the recurrence of bacterial vaginosis compared to a placebo. The study is randomized, double-blind, and placebo-controlled, focusing on women diagnosed with recurrent bacterial vaginosis who have recently completed antibiotic treatment. Participants will be randomly assigned to receive either the probiotic supplement or a placebo capsule daily for 12 weeks following standard antibiotic treatment. The probiotic aims to restore healthy vaginal bacteria, particularly Lactobacillus crispatus, which helps maintain vaginal balance. After the treatment period, participants will be followed for another 12 weeks to monitor for any recurrence of bacterial vaginosis. During the 24-week study, participants will undergo evaluations including vaginal pH measurement, symptom assessments for burning and itching, and monitoring for other genitourinary infections. Researchers will track treatment adherence, safety, and adverse events. The main goal is to see if the probiotic reduces episodes of recurrent bacterial vaginosis compared to placebo over the entire study period.
Actively Recruiting
Researchers are studying adults with fibrosing interstitial lung disease ILD, excluding idiopathic pulmonary fibrosis IPF, who have been diagnosed within the last three years and may be at risk of developing progressive pulmonary fibrosis PPF. The trial aims to evaluate the effects of a medicine called nerandomilast in slowing lung function decline and disease progression in this group. Participants are randomly assigned to one of two groups one takes nerandomilast tablets, and the other takes placebo tablets that look identical but contain no medicine. The study lasts up to about 2 years and 4 months, during which participants take their assigned tablets regularly and undergo scheduled assessments to monitor their lung condition. Throughout the study, participants visit the study site regularly for tests including spirometry to measure forced vital capacity FVC and diffusing capacity of the lungs for carbon monoxide DLCO. High-resolution computed tomography HRCT scans track lung changes over time. Researchers compare these results between groups to assess treatment effects, while monitoring overall health and any side effects.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
Researchers are studying the presence of micro- and nanoplastics MNPs in patients who have had a specific type of heart attack called ST segment elevation acute myocardial infarction STEMI. The study aims to understand how MNPs found in coronary blood clots relate to heart damage, plaque vulnerability, microvascular obstruction, and future heart-related events. This observational study will use imaging techniques like optical coherence tomography and cardiac magnetic resonance to explore these connections. The study involves patients undergoing urgent coronary angiography and thromboaspiration to remove blood clots. Researchers will compare those with MNPs in their clots to those without. Various assessments include measuring MNP levels in different vessels and biological samples, evaluating heart muscle damage, and analyzing plaque composition. The study will follow participants for up to one year to monitor heart events and recovery. Participants will undergo evaluations from enrollment through hospital discharge, including blood tests for inflammation and heart damage, imaging assessments, and monitoring of heart function and complications. Follow-up visits will occur up to one year after enrollment to assess cardiovascular events and heart function recovery. The primary outcomes focus on the burden of MNPs in coronary thrombi and their association with biomarkers and cardiac damage during the hospital stay, with extended observation for longer-term heart health outcomes.
Actively Recruiting
Researchers are investigating the presence and impact of microplastics and nanoplastics MNPs in adults with chronic coronary syndromes CCS undergoing coronary CT angiography CCTA and invasive coronary angiography. This observational study aims to analyze these particles in coronary blood and explore their relationship with coronary artery disease features, including plaque characteristics and vessel ischemia. Patients are followed up clinically at 1 and 3 years according to standard care. Participants undergo routine coronary CT angiography to assess suspected or known CCS and then invasive coronary angiography when clinically indicated. During invasive procedures, coronary blood samples are collected for central laboratory analysis of MNPs using specialized techniques such as pyrolysis-gas chromatography-mass spectrometry and laser direct infrared spectroscopy. The CCTA images are centrally evaluated to quantify and characterize coronary plaques. Patients are grouped based on the presence or absence of MNPs in coronary blood. Throughout the study, patients receive standard clinical management without changes to their care. Data collected include coronary blood MNP burden, plaque features from CCTA, and clinical outcomes such as major adverse cardiovascular events and mortality over 1- and 3-year follow-ups. The study monitors correlations between MNP levels and various imaging and clinical parameters to better understand their role in CCS progression and outcomes.
1-10 of 26
1